A randomized controlled trial evaluating the jiangniaosuan formulation as a treatment for hyperuricemic nephropathy at CKD stages 3-4 patients
- Conditions
- hyperuricemic nephropathy at CKD stages 3-4
- Registration Number
- ITMCTR2100005088
- Lead Sponsor
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria for uric acid nephropathy and TCM syndromes;
2. Age 18-75 years old, with independent behavior ability, no gender limitation;
3. Glomerular filtration rate: 15ml/min<=eGFRCKD-EPI-ASIA<60ml/min;
4. No renal replacement therapy;
5. Sign the informed consent to enter the clinical research.
1. Those with allergies or allergic constitution to the test drugs and control drugs;
2. Pregnant or lactating female patients;
3. Patients with abnormal liver function (ALT or AST exceeds the upper limit of normal by 2 times or more);
4. Combined with serious primary diseases such as nervous, cardiovascular, digestive, urinary, endocrine and hematopoietic systems, mental patients;
5. Those who are participating in other clinical drug trials;
6. Those who have received similar treatment within 2 weeks before the trial;
7. Patients with uric acid nephropathy with proteinuria (proteinuria>1g/d) or diabetes or hereditary kidney disease.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary N-acetyl-ß-D-glucosaminidase;Estimated glomerular filtration rate;Urinary ß2-microglobulin;
- Secondary Outcome Measures
Name Time Method Chinese medicine clinical symptom score;Urinary microalbumin-creatinine ratio;24-hour urinary protein quantity;Blood urea nitrogen;Serum uric acid;Serum creatinine;24-hour urine uric acid;Urinary retinol binding protein;Kidney B ultrasound;Nitric oxide;